Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

TY - JOUR

T1 - Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer

AU - Denmeade, Samuel R

AU - Jakobsen, Carsten M

AU - Janssen, Samuel

AU - Khan, Saeed R

AU - Garrett, Elizabeth S

AU - Lilja, Hans

AU - Christensen, S Brogger

AU - Isaacs, John T

PY - 2003/7/2

Y1 - 2003/7/2

N2 - Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is effective against both proliferative and quiescent (i.e., G0-arrested) cells. However, thapsigargin's mechanism of action indicates that it is unlikely to be selective for cancer cells or prostate cells.

AB - Standard anti-proliferative chemotherapy is relatively ineffective against slowly proliferating androgen-independent prostate cancer cells within metastatic sites. In contrast, the lipophilic cytotoxin thapsigargin, which causes apoptosis by disrupting intracellular free Ca2+ levels, is effective against both proliferative and quiescent (i.e., G0-arrested) cells. However, thapsigargin's mechanism of action indicates that it is unlikely to be selective for cancer cells or prostate cells.

KW - Animals

KW - Antineoplastic Agents

KW - Disease Models, Animal

KW - Humans

KW - Hydrolysis

KW - Male

KW - Mice

KW - Mice, Nude

KW - Prodrugs

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Thapsigargin

KW - Transplantation, Heterologous

KW - Treatment Outcome

M3 - Journal article

C2 - 12837835

SN - 1460-2105

VL - 95

SP - 990

EP - 1000

JO - National Cancer Institute. Journal (Online)

JF - National Cancer Institute. Journal (Online)

IS - 13

ER -